Farrsal
Financial news and analysis

Global insights for better decisions.

Economic, market and geopolitical coverage with clear context.

FarrsalNews for a Smarter Tomorrow
Financial news and analysis•2 min readPage 2 of 2

Replimune Posts $69.8 Million Q1 Loss as TUDRIQEV Approval Nears Commercial Launch

Replimune Group reported a net loss of $69.8 million, or $0.72 per basic and diluted share, for its fiscal first quarter ended June 30, 2026. The company held $…

Farrsal Editorial
Farrsal · News for a Smarter Tomorrow
f𝕏WAin
Replimune Posts $69.8 Million Q1 Loss as TUDRIQEV Approval Nears Commercial Launch
Article image: Replimune Posts $69.8 Million Q1 Loss as TUDRIQEV Approval Nears Commercial Launch

Article Highlights

Excerpts from the article

  • Replimune Group reported a net loss of $69.8 million, or $0.72 per basic and diluted share, for its fiscal first quarter ended June 30, 2026. The…
  • The FDA granted accelerated approval to TUDRIQEV in combination with nivolumab for adults with unresectable advanced cutaneous melanoma following…
  • Research and development expense was $49.3 million, compared with $57.8 million a year earlier. Selling, general and administrative expense was $19.0…

Options-implied volatility suggests the stock may move approximately 5.6% around the earnings release. The prior quarter's EPS miss of $0.76 versus a $0.73 consensus triggered a 7.27% after-hours decline.

The central question now is whether TUDRIQEV's commercial ramp can offset ongoing cash burn and legal overhang before the IGNYTE-3 readout in 2030?

Sources: Source 1 · Source 2 · Source 3 · Source 4 · Source 5 · Source 6

Latest News